Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger MS, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H.

Cancer Discov. 2018 May 25. pii: CD-18-0036. doi: 10.1158/2159-8290.CD-18-0036. [Epub ahead of print]

PMID:
29802158
2.

Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer.

Throm VM, Männle D, Giese T, Bauer AS, Gaida MM, Kopitz J, Bruckner T, Plaschke K, Grekova SP, Felix K, Hackert T, Giese NA, Strobel O.

Oncotarget. 2018 Jan 24;9(14):11734-11751. doi: 10.18632/oncotarget.24312. eCollection 2018 Feb 20.

3.

Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material.

Gress TM, Lausser L, Schirra LR, Ortmüller L, Diels R, Kong B, Michalski CW, Hackert T, Strobel O, Giese NA, Schenk M, Lawlor RT, Scarpa A, Kestler HA, Buchholz M.

Oncotarget. 2017 Nov 21;8(64):108223-108237. doi: 10.18632/oncotarget.22601. eCollection 2017 Dec 8.

4.

Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer.

Bauer AS, Nazarov PV, Giese NA, Beghelli S, Heller A, Greenhalf W, Costello E, Muller A, Bier M, Strobel O, Hackert T, Vallar L, Scarpa A, Büchler MW, Neoptolemos JP, Kreis S, Hoheisel JD.

Int J Cancer. 2018 Mar 1;142(5):1010-1021. doi: 10.1002/ijc.31087. Epub 2017 Oct 17.

5.

Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.

Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, Monast A, von Knebel Doeberitz M, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, Lathrop M, Park M, Büchler MW, Strobel O, Hackert T, Giese NA, Zogopoulos G, Sangwan V, Huang S, Riazalhosseini Y, Hoheisel JD.

Gastroenterology. 2016 Dec;151(6):1218-1231. doi: 10.1053/j.gastro.2016.08.040. Epub 2016 Aug 28.

PMID:
27578530
6.

Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Heller A, Angelova AL, Bauer S, Grekova SP, Aprahamian M, Rommelaere J, Volkmar M, Janssen JW, Bauer N, Herr I, Giese T, Gaida MM, Bergmann F, Hackert T, Fritz S, Giese NA.

Pancreas. 2016 Nov;45(10):1452-1460.

PMID:
27518460
7.

Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression.

Botla SK, Savant S, Jandaghi P, Bauer AS, Mücke O, Moskalev EA, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Gaida MM, Büchler MW, Strobel O, Hackert T, Giese NA, Augustin HG, Hoheisel JD.

Cancer Res. 2016 Jul 15;76(14):4149-59. doi: 10.1158/0008-5472.CAN-15-0390. Epub 2016 May 23.

8.

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR.

Nat Med. 2016 Mar;22(3):278-87. doi: 10.1038/nm.4038. Epub 2016 Feb 8.

9.

Isolation and culture of primary human pancreatic stellate cells that reflect the context of their tissue of origin.

Strobel O, Dadabaeva N, Felix K, Hackert T, Giese NA, Jesenofsky R, Werner J.

Langenbecks Arch Surg. 2016 Feb;401(1):89-97. doi: 10.1007/s00423-015-1343-6. Epub 2015 Dec 29.

PMID:
26712717
10.

PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.

Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, Krattenmacher A, Geisel B, Kraus JM, Frese KK, Kelkenberg S, Giese NA, Kestler HA, Gress TM, Buchholz M.

Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.

11.

Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.

Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, Hackert T, Hinz U, Hussain SP, Kozlov SV, Ashwell JD.

Nat Med. 2015 Nov;21(11):1337-43. doi: 10.1038/nm.3957. Epub 2015 Oct 19.

12.

Stratification of pancreatic tissue samples for molecular studies: RNA-based cellular annotation procedure.

Heller A, Gaida MM, Männle D, Giese T, Scarpa A, Neoptolemos JP, Hackert T, Strobel O, Hoheisel JD, Giese NA, Bauer AS.

Pancreatology. 2015 Jul-Aug;15(4):423-31. doi: 10.1016/j.pan.2015.05.480. Epub 2015 Jun 15.

13.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

14.

Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.

Zhang Y, Liu L, Fan P, Bauer N, Gladkich J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, Hinz U, Gross W, Fortunato F, Herr I.

Oncotarget. 2015 Apr 30;6(12):9999-10015.

15.

Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity.

Schenk M, Aykut B, Teske C, Giese NA, Weitz J, Welsch T.

Cancer Lett. 2015 Mar 28;358(2):161-169. doi: 10.1016/j.canlet.2014.12.037. Epub 2014 Dec 18.

PMID:
25529011
16.

Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.

Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, Zöller M.

Int J Cancer. 2015 Jun 1;136(11):2616-27. doi: 10.1002/ijc.29324. Epub 2014 Nov 25.

17.

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.

Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, Innocenti F, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, LaCroix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PH, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT.

Nat Genet. 2014 Sep;46(9):994-1000. doi: 10.1038/ng.3052. Epub 2014 Aug 3.

18.

Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.

Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA.

PLoS One. 2014 Jun 16;9(6):e100178. doi: 10.1371/journal.pone.0100178. eCollection 2014.

19.

Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.

Hartmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Ryschich E.

Clin Cancer Res. 2014 Jul 1;20(13):3422-33. doi: 10.1158/1078-0432.CCR-13-2972. Epub 2014 Apr 24.

20.

Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, Daeffler L, Rommelaere J, Werner J, Raykov Z, Giese NA.

J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.

21.

Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.

Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M.

Int J Cancer. 2014 Jun 1;134(11):2572-82. doi: 10.1002/ijc.28597. Epub 2013 Nov 25.

22.

Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis.

Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algül H, Friess H, Ceyhan GO.

PLoS One. 2013;8(3):e60529. doi: 10.1371/journal.pone.0060529. Epub 2013 Mar 28.

23.

TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells.

Raykov Z, Grekova SP, Hörlein R, Leuchs B, Giese T, Giese NA, Rommelaere J, Zawatzky R, Daeffler L.

PLoS One. 2013;8(1):e55086. doi: 10.1371/journal.pone.0055086. Epub 2013 Jan 29.

24.

The impact of MFG-E8 in chronic pancreatitis: potential for future immunotherapy?

D'Haese JG, Demir IE, Kehl T, Winckler J, Giese NA, Bergmann F, Giese T, Büchler MW, Friess H, Hartel M, Ceyhan GO.

BMC Gastroenterol. 2013 Jan 16;13:14. doi: 10.1186/1471-230X-13-14.

25.

Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system.

Fredebohm J, Boettcher M, Eisen C, Gaida MM, Heller A, Keleg S, Tost J, Greulich-Bode KM, Hotz-Wagenblatt A, Lathrop M, Giese NA, Hoheisel JD.

PLoS One. 2012;7(11):e48503. doi: 10.1371/journal.pone.0048503. Epub 2012 Nov 12.

26.

Neuronal plasticity in chronic pancreatitis is mediated via the neurturin/GFRα2 axis.

Demir IE, Wang K, Tieftrunk E, Giese NA, Xing B, Friess H, Kehl T, Ceyhan GO.

Am J Physiol Gastrointest Liver Physiol. 2012 Nov 1;303(9):G1017-28. doi: 10.1152/ajpgi.00517.2011. Epub 2012 Sep 6.

27.

Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia.

Skorokhod A, Bachmann J, Giese NA, Martignoni ME, Krakowski-Roosen H.

BMC Cancer. 2012 Jun 21;12:265. doi: 10.1186/1471-2407-12-265.

28.

Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.

Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T, Galabov A, Heller A, Giese NA, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2011 Nov 15;12(10):888-95. doi: 10.4161/cbt.12.10.17678. Epub 2011 Nov 15.

29.

Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.

Welsch L, Welsch T, Dovzhanskiy DI, Felix K, Giese NA, Krysko DV, Werner J.

Int J Oncol. 2012 Feb;40(2):427-35. doi: 10.3892/ijo.2011.1239. Epub 2011 Oct 21.

PMID:
22020984
30.

Prognostic significance of erythropoietin in pancreatic adenocarcinoma.

Welsch T, Zschäbitz S, Becker V, Giese T, Bergmann F, Hinz U, Keleg S, Heller A, Sipos B, Klingmüller U, Büchler MW, Werner J, Giese NA.

PLoS One. 2011;6(8):e23151. doi: 10.1371/journal.pone.0023151. Epub 2011 Aug 1.

31.

Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.

Adwan H, Zhivkova-Galunska M, Georges R, Eyol E, Kleeff J, Giese NA, Friess H, Bergmann F, Berger MR.

Br J Cancer. 2011 Jul 12;105(2):288-95. doi: 10.1038/bjc.2011.217. Epub 2011 Jun 28.

32.

Identification of serum proteins involved in pancreatic cancer cachexia.

Felix K, Fakelman F, Hartmann D, Giese NA, Gaida MM, Schnölzer M, Flad T, Büchler MW, Werner J.

Life Sci. 2011 Jan 31;88(5-6):218-25. doi: 10.1016/j.lfs.2010.11.011. Epub 2010 Nov 19.

PMID:
21094171
33.

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA.

Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19.

34.

Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer.

Jiang X, Gillen S, Esposito I, Giese NA, Michalski CW, Friess H, Kleeff J.

Histol Histopathol. 2010 Dec;25(12):1497-506. doi: 10.14670/HH-25.1497.

PMID:
20886430
35.

Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.

Gaida MM, Haag N, Günther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J, Wente MN.

Int J Mol Med. 2010 Aug;26(2):281-8.

PMID:
20596609
36.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ.

Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3.

37.

Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.

Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, Bergmann F, Schmidt J, Werner J, Buchler MW, Jaeger D, Giese NA.

Cancer Immunol Immunother. 2010 Sep;59(9):1389-400. doi: 10.1007/s00262-010-0870-9. Epub 2010 Jun 1.

PMID:
20514540
38.

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cristea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC.

Blood. 2010 Sep 2;116(9):1460-8. doi: 10.1182/blood-2009-06-222943. Epub 2010 May 26.

39.

Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells.

Erkan M, Weis N, Pan Z, Schwager C, Samkharadze T, Jiang X, Wirkner U, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J.

Mol Cancer. 2010 Apr 23;9:88. doi: 10.1186/1476-4598-9-88.

40.

Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma.

Ceyhan GO, Schäfer KH, Kerscher AG, Rauch U, Demir IE, Kadihasanoglu M, Böhm C, Müller MW, Büchler MW, Giese NA, Erkan M, Friess H.

Ann Surg. 2010 May;251(5):923-31. doi: 10.1097/SLA.0b013e3181d974d4.

PMID:
20395845
41.

Reduced α-dystroglycan expression correlates with shortened patient survival in pancreatic cancer.

Jiang X, Rieder S, Giese NA, Friess H, Michalski CW, Kleeff J.

J Surg Res. 2011 Nov;171(1):120-6. doi: 10.1016/j.jss.2009.11.730. Epub 2009 Dec 22.

PMID:
20338590
42.

Seromic profiling of ovarian and pancreatic cancer.

Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, Andrews C, Ritter G, Old LJ, Odunsi K, Jäger D.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5088-93. doi: 10.1073/pnas.0914213107. Epub 2010 Mar 1.

43.

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer.

Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H.

BMC Cancer. 2009 Dec 26;9:463. doi: 10.1186/1471-2407-9-463.

44.

The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells.

Abiatari I, Gillen S, DeOliveira T, Klose T, Bo K, Giese NA, Friess H, Kleeff J.

Int J Oncol. 2009 Nov;35(5):1111-6.

PMID:
19787265
45.

Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.

Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, Büchler MW, Friess H, Esposito I, Kleeff J.

Cancer Biol Ther. 2009 Aug;8(16):1527-33. Epub 2009 Aug 13.

PMID:
19571666
46.

Consensus transcriptome signature of perineural invasion in pancreatic carcinoma.

Abiatari I, DeOliveira T, Kerkadze V, Schwager C, Esposito I, Giese NA, Huber P, Bergman F, Abdollahi A, Friess H, Kleeff J.

Mol Cancer Ther. 2009 Jun;8(6):1494-504. doi: 10.1158/1535-7163.MCT-08-0755. Epub 2009 Jun 9.

47.

Neural fractalkine expression is closely linked to pain and pancreatic neuritis in human chronic pancreatitis.

Ceyhan GO, Deucker S, Demir IE, Erkan M, Schmelz M, Bergmann F, Müller MW, Giese T, Büchler MW, Giese NA, Friess H.

Lab Invest. 2009 Mar;89(3):347-61. doi: 10.1038/labinvest.2008.170. Epub 2009 Jan 19.

48.

Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.

Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z.

Clin Cancer Res. 2009 Jan 15;15(2):511-9. doi: 10.1158/1078-0432.CCR-08-1088.

49.

Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.

Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW, Friess H.

Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028. Epub 2008 Dec 31.

PMID:
19118941
50.

Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer.

Jiang X, Abiatari I, Kong B, Erkan M, De Oliveira T, Giese NA, Michalski CW, Friess H, Kleeff J.

Pancreatology. 2009;9(1-2):165-72. doi: 10.1159/000178888. Epub 2008 Dec 13.

PMID:
19077468

Supplemental Content

Loading ...
Support Center